Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of “Hold” from Brokerages

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have earned an average recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $33.1667.

Several equities analysts recently weighed in on the company. Mizuho reduced their target price on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. Wall Street Zen downgraded shares of Upstream Bio from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. JPMorgan Chase & Co. lowered shares of Upstream Bio from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $35.00 to $8.00 in a report on Friday, June 12th. HC Wainwright began coverage on shares of Upstream Bio in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 target price on the stock. Finally, Weiss Ratings downgraded shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th.

Upstream Bio Stock Performance

Shares of NASDAQ UPB opened at $7.53 on Monday. The company’s 50-day moving average price is $7.62 and its 200 day moving average price is $13.76. Upstream Bio has a 52 week low of $5.85 and a 52 week high of $33.68. The stock has a market cap of $409.78 million, a price-to-earnings ratio of -2.59 and a beta of 1.23.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). The company had revenue of $1.03 million during the quarter, compared to analyst estimates of $1.03 million. Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%. As a group, research analysts expect that Upstream Bio will post -2.9 earnings per share for the current year.

Institutional Trading of Upstream Bio

Several institutional investors have recently made changes to their positions in the stock. ADAR1 Capital Management LLC purchased a new position in shares of Upstream Bio in the 1st quarter worth $315,000. California State Teachers Retirement System grew its position in Upstream Bio by 170.7% during the first quarter. California State Teachers Retirement System now owns 39,661 shares of the company’s stock valued at $357,000 after acquiring an additional 25,009 shares during the period. The Manufacturers Life Insurance Company increased its stake in Upstream Bio by 51.2% during the first quarter. The Manufacturers Life Insurance Company now owns 15,338 shares of the company’s stock worth $138,000 after acquiring an additional 5,191 shares during the last quarter. Quantinno Capital Management LP increased its stake in Upstream Bio by 220.4% during the first quarter. Quantinno Capital Management LP now owns 49,389 shares of the company’s stock worth $445,000 after acquiring an additional 33,974 shares during the last quarter. Finally, Entropy Technologies LP acquired a new position in shares of Upstream Bio in the 1st quarter valued at about $210,000.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.